According to the World Health Organization (WHO), unwanted the effects are classified according to their frequency of development as follows: very often (≥1/10), often (≥1/100, <1/10), infrequently (≥1/1000, <1/100), rarely (≥1/10000, <1/1000) and very rarely (<1/10000); frequency is unknown (the frequency of occurrence of phenomena can not be determined on the basis of available data).
On the part of the organs of hematopoiesis and lymphatic system
infrequently: leukopenia (in 3-5% of patients), characterized mainly by a decrease in the number of neutrophils; the maximum decrease in the level of leukocytes is observed on the 2-4th day after the start of treatment, then their level is normalized within 2-3 days, while the continuation of treatment with Dermazin® does not affect the recovery of the number of leukocytes.
According to post-marketing observations, the following adverse reactions were identified:
On the part of the organs of hematopoiesis and lymphatic system
frequency is unknown: increase osmolality of the blood plasma.
From the immune system
frequency is unknown: hypersensitivity reactions.
From the skin and subcutaneous structures
rarely: Stevens-Johnson syndrome, toxic epidermal necrolysis;
frequency is unknown: allergic skin reactions such as rash, itching, contact dermatitis, gray staining of the skin under sunlight.
General disorders and disorders at the site of application
frequency is unknown: burning sensation or pain.
Systemic absorption of silver sulfadiazine in very rare cases can cause adverse reactions similar to those in systemic therapy with sulfonamides (skin rash, Stevens-Johnson syndrome, exfoliative dermatitis,multiforme erythema, interstitial nephritis, eosinophilia, eczema, water-electrolyte imbalance, fever, hypoglycemia, purpura, photodermatosis, erythema nodosum, headache, joint pain, folic acid deficiency).